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Abstract
Background: Targeted therapies are based on exploiting cancer-cell-specific genetic features or phenotypic traits
to selectively kill cancer cells while leaving normal cells unaffected. Oxidative stress is a cancer hallmark phenotype.
Given that free nucleotide pools are particularly vulnerable to oxidation, the nucleotide pool sanitising enzyme,
MTH1, is potentially conditionally essential in cancer cells. However, findings from previous MTH1 studies have been
contradictory, meaning the relevance of MTH1 in cancer is still to be determined. Here we ascertained the role of
MTH1 specifically in lung cancer cell maintenance, and the potential of MTH1 inhibition as a targeted therapy strategy
to improve lung cancer treatments.
Methods: Using siRNA-mediated knockdown or small-molecule inhibition, we tested the genotoxic and cytotoxic
effects of MTH1 deficiency on H23 (p53-mutated), H522 (p53-mutated) and A549 (wildtype p53) non-small cell lung
cancer cell lines relative to normal MRC-5 lung fibroblasts. We also assessed if MTH1 inhibition augments current
therapies.
Results: MTH1 knockdown increased levels of oxidatively damaged DNA and DNA damage signaling alterations in all
lung cancer cell lines but not normal fibroblasts, despite no detectable differences in reactive oxygen species levels
between any cell lines. Furthermore, MTH1 knockdown reduced H23 cell proliferation. However, unexpectedly, it did
not induce apoptosis in any cell line or enhance the effects of gemcitabine, cisplatin or radiation in combination
treatments. Contrastingly, TH287 and TH588 MTH1 inhibitors induced apoptosis in H23 and H522 cells, but only
increased oxidative DNA damage levels in H23, indicating that they kill cells independently of DNA oxidation and
seemingly via MTH1-distinct mechanisms.
Conclusions: MTH1 has a NSCLC-specific p53-independent role for suppressing DNA oxidation and genomic
instability, though surprisingly the basis of this may not be reactive-oxygen-species-associated oxidative stress.
Despite this, overall our cell viability data indicates that targeting MTH1 will likely not be an across-the-board
effective NSCLC therapeutic strategy; rather it induces non-cytotoxic DNA damage that could promote cancer
heterogeneity and evolution.
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Background
Cancer cells harbour genetic mutations and exhibit
phenotypic traits that are not found in normal cells.
These cancer-specific features may provide avenues for
the development of targeted therapies that selectively kill
cancer cells [1]. The development of such strategies is a
major focus of current cancer research. One such ap-
proach is synthetic lethality, which is when an acquired
defect in a particular factor or pathway renders cancer
cells sensitive to inhibition of another second specific fac-
tor. Still, this approach is often limited to a certain context
or cancer type, for example, inhibiting poly (ADP-ribose)
polymerase (PARP) in BRCA1- and BRCA2-deficient
breast and ovarian cancers [2, 3]. An alternative though
related strategy that may be more effective in treating a
wider range of cancers is cancer phenotypic lethality,
which is to target factors and cell processes that are non-
essential in normal cells but that become essential for cell
growth following the acquisition of hallmark cancer traits
[1, 4–6]. However, until such pathways are identified and
validated for therapeutic potential, radiotherapy- and
chemotherapy-based treatments that are often associated
with side-effects and resistance will remain the mainstay
of treatments.
Oxidative stress, which arises when there is an imbalance
between the production of reactive oxygen species (ROS)
and the ability of a cell to counteract their levels or effects,
is a hallmark cancer trait that can drive both carcinogen-
esis and continuing tumour evolution [4, 7]. Paradoxically,
ROS are the basis of much of the cytotoxicity of radiother-
apy and several chemotherapy treatments. Hence, there
may be several normally non-essential oxidative stress re-
sponse factors and pathways that become ‘conditionally es-
sential’ in cancer cells and/or significantly affect therapy
responses.
ROS can react with all components of DNA to cause
numerous types of lesions [8]. However, the free deoxyri-
bonucleoside triphosphate (dNTP) pool is reportedly
190–13,000 times more susceptible to modification than
DNA [9]. This suggests that a significant proportion of
oxidative-stress-induced DNA damage arises via misincor-
poration of oxidised dNTPs during DNA replication ra-
ther than direct DNA modification. Oxidised DNA bases
do not majorly disrupt DNA structure; however, they can
subsequently lead to secondary types of DNA damage
such as DNA mispairs [10], DNA single-strand breaks
(SSBs) that arise when DNA glycosylases remove damaged
bases during base excision repair (BER), and DNA double-
strand breaks (DSBs) [11] that arise through poorly de-
fined mechanisms possibly due to DNA replication stress.
DSBs in particular are highly genotoxic and cytotoxic if
not repaired correctly. This leads to the prediction that
the pathways involved in preventing oxidised DNA base
misincorporation could be critical in either promoting or
suppressing cancer development and evolution depending
on context [12].
Mut T Homologue 1 (MTH1) is a Nudix hydrolase
family enzyme member that hydrolyses selected oxidised
dNTP and NTP substrates to the corresponding mono-
phosphate products and inorganic pyrophosphate to pre-
vent their misincorporation into DNA and RNA respect-
ively [13–15]. Primary substrates of MTH1 are dNTPs
containing 8-oxo-7,8-dihydroguanine (8-oxoGua), one of
the most common types of ROS-induced lesions [16],
and 2-hydroxy-adenine. Supporting the idea of a role in
cancer cell maintenance, MTH1 levels are elevated in
various cancers [17–21], while lower MTH1 levels in
U2OS osteosarcoma cells and non-small cell lung cancer
(NSCLC) patient samples correlates with increased levels
of DNA oxidation [22, 23]. MTH1 overexpression in
oncogene-expressing human cells promoted transform-
ation [11, 24, 25], while knockdown leads to DNA-
replication-associated DNA damage response (DDR) ac-
tivation and senescence [11, 26]. Accordingly, the first
developed MTH1 inhibitors appear to selectively inhibit
cancer cell growth [22, 27]. Collectively, these findings
suggested that as cells undergo malignant transform-
ation and acquire the trait of oxidative stress, MTH1 be-
comes essential for maintaining genome integrity and
cell viability. This implies that targeting MTH1 activity
could form the basis of a new targeted therapy strategy
[1, 28]. However, other recent data challenged these ob-
servations and conclusions. In these studies, MTH1 defi-
ciency did not hinder the growth of HeLa, SW480 or
U2OS cells, and highly specific MTH1 inhibitors dis-
played only weak cancer cell cytotoxicity [29–31]. The
title of the recent review, “MTH1 as a chemotherapeutic
target: the elephant in the room” [32], highlights the fact
that the differing opinions and conclusions remain unre-
solved. Hence, it has become critically important to
undertake further work to shed light on these contra-
dictory findings and better understand the relevance of
MTH1 in cancer and therapy.
Lung cancer is the leading cause of cancer death world-
wide [33]. Despite improvements in survival rates for many
other cancer types in recent years, NSCLC therapy re-
sponses and patient outcomes have not significantly im-
proved [33, 34]. In our study, we addressed two main
objectives to enable the assessment of the potential of
MTH1 inhibition as a NSCLC targeted therapy strategy.
First, we assessed if MTH1 deficiency alone is genotoxic or
cytotoxic to several lung cell lines, and whether these ef-
fects were highly selective to NSCLC cells relative to nor-
mal cells. Second, we evaluated potential new combination
therapy strategies by testing if targeting MTH1 enhanced
the effects of current therapeutic agents. Thus, we tackle
the currently opposing and contentious opinions on the
significance of MTH1 in cancer biology and therapy [1, 35].
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Methods
Cell lines and chemicals
A549 (CCL-185; wildtype p53), H522 (CRL-5810; p53
mutation c.572delC, p.P191fs*56), H23 (CRL-5800; p53
mutation c.738G > C, p.M246I) and MRC-5 (CCL-171;
wildtype p53) cell lines were purchased fully authenticated
from ATCC (p53 mutation information provided at
https://www.atcc.org/Documents/Learning_Center/~/media/
5F7B1CCACF724E3398BE56BFBEE3EFE4.ashx). MRC-5
and A549 cell lines were cultured in EMEM (ATCC) and
DMEM-high glucose (ThermoFisher Scientific) media re-
spectively, and H522 and H23 cells in RPMI 1640 medium
ATCC modification. All media were supplemented with 10%
(v/v) FBS (ThermoFisher Scientific). Cells were cultured at
37 °C in a humidified atmosphere (95% air / 5% CO2) and
maintained at a low passage by not passaging beyond
6 months’ post resuscitation. Cisplatin, gemcitabine, VP-16
(etoposide), phleomycin, hydroxyurea and MTH1 small mol-
ecule inhibitors (TH287, TH588) were purchased from
Sigma-Aldrich.
siRNA transfections
These were performed using DharmaFECT 1 reagent
(GE Healthcare) according to manufacturer’s instruc-
tions. Briefly, a transfection complex was prepared by in-
cubating together for 20 min at room temperature, 7.
5 μl DharmaFECT 1 reagent, 125 μl Opti-MEM medium
(ThermoFisher Scientific) and siRNA diluted in 125 μl
Opti-MEM medium (final siRNA concentrations were
20 and 15 nM for H522 and remaining cell lines,
respectively). 3 X 105 cells were plated with the
transfection complex and incubated for 24 h in Opti-
MEM medium, after which the transfection media was
replaced with standard medium. MTH1-siRNA oligo-
nucleotide 5′- > 3′ sequences (ThermoFisher Scientific)
were sense CAUCUGGAAUUAACUGGAUtt and anti-
sense AUCCAGUUAAUUCCAGAUGaa. Silencer Select
Negative Control 1 siRNA (ThermoFisher Scientific) was
used as scramble siRNA control.
Modified alkaline comet assay
DNA damage was assessed using Formamidopyrimidine-
DNA glycosylase (Fpg)-modified comet assay that is a
slight modification of the original method [36]. Briefly,
slides containing cells embedded in 0.6% low melting
point agarose were incubated overnight at 4 °C in lysis
buffer (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris-
base, 1% Triton X-100, pH 10) (chemicals purchased
from Sigma-Aldrich). Lysed cells were treated with Fpg
(final concentration 0.8 U/gel) for 30 min at 37 °C, and
subjected to alkaline electrophoresis in buffer containing
300 mM NaOH, 1 mM Na2EDTA, pH 13. Following
neutralization with 0.4 M Tris-base, pH 7.5, slides were
stained with 2.5 μg/ml propidium iodide (PI) and dried
at 37 °C. Comets were visualised at Χ200 magnification
using an Olympus BH-2-RFL-T2 fluorescent microscope
fitted with an excitation filter of 515–535 nm and a
590 nm barrier filter, and images were captured via a
high performance CCDC camera (COHU MOD 4912–
5000/0000). % tail DNA was calculated using Komet
software (Andor Technology). For radiation treatments,
the Xstrahl RS320 X-Ray Irradiator system was used to
expose agarose-embedded cells on ice (assessments of
immediate DNA damage) or cells in suspension that
were then cultured for 24 h (recovery samples). In the
MTH1 inhibitor experiments, cells growing in complete
medium were treated with 10 μM TH287 or TH588 for
24 h prior to collection.
ROS level measurements
30,000 cells per well were seeded in triplicate in black 96
well plates (Porvair) and cultured for 24 h. Cells were
washed with 200 μl PBS prior to the addition of 1 μl
H2DCF-DA (ThermoFisher Scientific) and incubated in
the dark for 30 min in a humidified atmosphere at 37 °C.
200 μl PBS was then added to all the wells, and the relative
ROS-induced fluorescence intensities were measured im-
mediately on a FLUOstar OPTIMA Microplate Reader
(BMG Labtech; 485 nm excitation and 520 nm emission
wavelengths). 30-min pre-treatment with 9.8 mM hydro-
gen peroxide was used for positive controls (relatively high
dose used to overcome the scavenging of extracellular
hydrogen peroxide by sodium pyruvate in the media [37]).
Samples without seeded cells used as blanks.
WST-1 cell proliferation assay
WST-1 is a water-soluble tetrazolium salt that is cleaved
to a formazan dye in a mechanism mainly dependent on
NAD(P)H production by metabolically active cells. 2 days
after transfection, 1 X 104 cells (2 X 104 for H522) were
seeded in triplicate for each sample in clear flat bottom
96 well plates, and left for 3 days before performing the
assay according to manufacturer’s instructions (Sigma-
Aldrich). Briefly, 10 μl Cell Proliferation Reagent WST-1
was added to each well containing 100 μl media and in-
cubated for 30 min to 4 h. Absorbance values (that
ranged between 0.5–2) were determined on an ELx808
microplate reader (BIO-TEK Instruments) at 450 nm
against a blank control background. Cell proliferation
(%) was determined by calculating (mean absorbance of
sample / mean absorbance of control) X 100. 2-day VP-
16 (Sigma-Aldrich) treatments were used as positive
controls.
Annexin V/PI apoptosis assay
Double staining with annexin V-FITC (apoptosis marker)/
PI combined with flow cytometry was applied as described
in manufacturer’s instructions (Affymetrix). VP-16 was
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used as a positive control, while 4 untreated negative con-
trol cells were included for instrumental compensation
and gating: no stain, PI only, annexin V-FITC only, and
both PI and annexin V-FITC. Samples were analysed on a
BD FACSCanto™ II flow cytometer (BD Biosciences) using
BD FACSDiVa™ v6.1.3 software. At least 10,000 events
were acquired per sample.
Western blot analysis
Standard techniques were used. Briefly, protein samples
were prepared using Laemmli buffer lysis and sonication
(15 s at 14 μm using Soniprep 150). MTH1, MTH2 and α-
tubulin antibodies were purchased from Abcam, and
CHK1 (2G1D5), phospho-CHK1 (Ser345), phospho-CHK2
(Thr68) from Cell Signaling Technology. Polyclonal sec-
ondary antibodies were horseradish-peroxidase-conjugated,
and detection was performed using ECL substrate (Pierce)
and X-ray film (CL-XPosure). Band intensities were quanti-
fied using densitometry GeneSnap or Image J 1.49 version
software.
Data analysis and statistical tests
GraphPad Prism software (version 7 and 6.05) was used
to calculate mean ± standard deviation (S.D) or standard
error mean (SEM). Unless otherwise stated in the figure
legend, data was evaluated by one-way ANOVA followed
by post-hoc Tukey’s multiple comparison test to com-
pare values between two or more groups. P-value < 0.05
was considered as statistically significant. The number of
independent experimental repeats are indicated in each
figure or figure legend.
Results
MTH1 deficiency increases levels of DNA oxidation in
NSCLC cells but not normal lung fibroblasts
In order to observe the effects of MTH1 deficiency we used
siRNA to successfully knockdown MTH1 in various lung
cell lines. We targeted MTH1 in H23 adenocarcinoma
(p53-mutated), H522 adenocarcinoma (p53-mutated) and
A549 lung carcinoma (wildtype p53) NSCLC cell lines in
order to assess if any observed effects are applicable to
NSCLC in general and/or are dependent on p53 status, and
in MRC-5 normal lung cells to determine if the effects are
cancer specific. Though MTH1 is elevated in some cancers
[17–21], endogenous MTH1 levels were not significantly
different between the NSCLC and MRC-5 cell lines. H522
had the lowest MTH1 level, but the levels in H23, A549
and MRC-5 were only 1.3-, 1.4- and 1.2-fold higher, re-
spectively (Additional file 1). MTH1 levels were signifi-
cantly reduced 3 days after MTH1 siRNA transfection,
averaging decreases of 88% in H23, 83% in A549 and 76%
in MRC-5, and remained low for at least 6 days (Fig. 1a, b
and d). MTH1 knockdown efficiency was slightly delayed
in H522 cells, but MTH1 levels still decreased by 70%
inhibition by day 4 (Fig. 1c). The levels of MTH1 depletion
were comparable to those in previous published studies
[11, 38]. Hence, using siRNA we were able to study the role
of MTH1 in various NSCLC cell lines and normal lung
cells. The level of another Nudix hydrolase family enzyme
member, MTH2, did not increase following MTH1 knock-
down (Additional file 2), suggesting it does not act to com-
pensate for loss of MTH1. This is concordant with a recent
study that found MTH2 has a preference for nucleotide
substrates different to those of MTH1 [39].
To begin to determine if significantly reduced MTH1
levels lead to functional consequences in different lung
cell lines, we first assessed the effects of MTH1 knock-
down on DNA oxidation levels using the Fpg-modified
alkaline comet assay (Additional file 3). Cells were col-
lected 4 days after siRNA transfection to provide suffi-
cient time for them to have undergone DNA replication
in the presence of notably reduced MTH1 levels. Follow-
ing MTH1 knockdown, we consistently observed signifi-
cant 1.5- to 2-fold increases in oxidatively damaged
DNA bases (i.e. Fpg-sensitive sites) in H23, H522 and
A549 genomic DNA relative to the scrambled siRNA
controls, but no difference in MRC-5 (Fig. 2a - d). This
finding is concordant with the notion that MTH1 acts to
suppress the misincorporation of oxidised dNTPs specif-
ically in cancer cells. We observed no increases in DNA
SSB levels (i.e. Fpg-independent sites), which contrasts
with a previous observation in A549 cells [25]. The rea-
son for this contradiction is unclear; however, unless a
cell line also harbours a BER defect that leads to the
generation of more or longer-lived SSB intermediates
following initial damaged base removal [40], we would
not predict an increase in SSB levels following MTH1
knockdown.
To assess if the conditional requirement for MTH1 is
due to cancer-associated oxidative stress we measured ROS
levels in all cell lines. However, we found no differences be-
tween any of the NSCLC lines and MRC-5 (Fig. 2e). This is
consistent with there being no significant differences be-
tween any of the cell lines in the background levels of DNA
oxidation and SSBs (Fig. 2a - d), but implies that the basis
of the requirement for MTH1 to suppress DNA oxidation
in NSCLC cells is not simply due to higher ROS levels. This
finding goes against previous proposed models [22, 25].
Given all the genetic and signaling disturbances within can-
cer cells, there may be many other causes of this MTH1 de-
pendency that remain to be discovered.
MTH1 is not required in response to exogenous sources
of oxidative stress
Hydrogen peroxide treatment was previously shown to
lead to the accumulation of genomic 8-oxoGua and cell
death in MTH1−/− mouse embryonic fibroblasts [41],
indicating that oxidative stress can be cytotoxic in a
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MTH1-deficient background. We proposed that in
addition to a role in processing endogenously-generated
oxidised dNTPs within NSCLC cells, MTH1 would also
be required to suppress the misincorporation of damaged
DNA bases following exposure to exogenous sources of
oxidative stress and anti-cancer agents. To determine this,
we first assessed whether higher DNA oxidation levels
were detectable in MTH1-deficient H23 cells after irradi-
ation (IR) treatment, which targets the nucleotide pool
[42]. Cell samples were analysed immediately after IR and
following a 24-h recovery, which was permitted to allow
enough time for IR-generated oxidised dNTPs to be mis-
incorporated. The relative increases in SSB levels and oxi-
datively damaged DNA immediately after IR did not differ
between the scramble siRNA control and MTH1-deficient
cultures (Fig. 2f), confirming that MTH1 does not have a
role in preventing direct oxidation of DNA. However, by
24 h post-IR, the relative levels of oxidatively damaged
DNA in all samples had returned to levels comparable to
those prior to IR. A similar observation was seen when
oxidative stress was induced after treatment with the
model oxidant (non-radical ROS), hydrogen peroxide
(Additional file 4). Overall, this suggests that MTH1 is not
required to prevent the misincorporation of dNTPs that
are oxidised via exogenous agents. Alternatively, other
MTH1-independent compensatory factors such as Ogg1
may be activated when very high levels of damaged
dNTPS are acutely generated [43].
MTH1 deficiency induces alterations in DNA damage
response signaling
We propositioned that the increased levels of oxidised
DNA bases caused by MTH1 knockdown may lead to
DNA replication stress in NSCLC cell lines, while nor-
mal cells would remain genomically stable. The central
kinase pathways in the DNA-replication-associated DDR
are ATR-CHK1 and ATM-CHK2, which are initially acti-
vated by defective DNA replication forks and DSBs re-
spectively [44]. Using Western blotting, we detected
indications of DDR alterations in all NSCLC cells lines
following MTH1 knockdown (Fig. 3), suggesting that the
cells were responding to replication stress and some
a c
b d
Fig. 1 MTH1 is efficiently knocked down in various lung cancer cell lines and normal lung fibroblasts. Western blots to determine MTH1 protein
levels in cell cultures grown in media without transfection reagent (no siRNA), or following transfection with MTH1 siRNA or scramble siRNA.
a H23. b A549. c H522. d MRC-5. Representative day 4 blots shown. Day 4 MTH1 band intensities were normalized to corresponding α-Tubulin
loading control bands, and then siRNA samples were normalised to corresponding no siRNA bands. Numbers of independent experiments (n) are
indicated. Mean values and SD were calculated from the normalised values of the independent experiments. Error bars represent SD. Asterisks
represent a significant difference between MTH1 siRNA and corresponding no siRNA normalised values (****P < 0.0001, *P < 0.05)
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a c
b d
e
f
Fig. 2 MTH1 knockdown leads to increased oxidised DNA base levels in lung cancer cell genomes. Formamidopyrimidine-DNA glycosylase (Fpg)-
modified alkaline comet assay to determine DNA damage levels (expressed as % tail DNA) in individual cells grown in media without transfection
reagent (no siRNA), or 4 days after transfection with MTH1 siRNA or scramble siRNA. DNA single-strand breaks detected as Fpg-independent
signal, while oxidatively damaged DNA bases detected by treatment with Fpg. a H23, 8 independent experiments. b A549, 3 independent experiments.
c H522, 4 independent experiments. d MRC-5, 3 independent experiments. For (a) to (d), 200 randomly selected individual comets were scored for
each sample per experiment. Mean values from independent experiments were used to generate final mean values and SD. Error bars represent SD.
Asterisks indicate a significant difference between Fpg-treated MTH1 siRNA and scramble siRNA experiment means (****P < 0.0001, ***P < 0.001,
*P < 0.05); ns, not significant. e Internal ROS levels determined by measuring fluorescence signal induced by 2′,7′-dichlorodihydrofluorescein
diacetate oxidisation. RFU, relative fluorescence units. Blank samples were without seeded cells. Mean values were calculated from 4 independent
experiments. Error bars represent SD calculated from the independent experiment values. Unpaired T-test was performed. Asterisks indicate a
significant difference between hydrogen peroxide treated and untreated samples (***P < 0.001, **P < 0.01 and *P < 0.05). f Comet assay post-ir-
radiation of H23 cells. Error bars represent SEM calculated from 400 individual comet values analysed in total from 2 independent experiments. No stat-
istical analysis was performed
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kind of secondary DNA damage. Surprisingly, however,
the DDR responses in different NSCLC cell lines varied
in the pathways affected and whether they were acti-
vated or repressed.
We detected DDR activation in MTH1-knockdown
H522 cells, as indicated by an approximately 2-fold in-
crease in CHK2 phosphorylation levels relative to no
siRNA and scramble siRNA controls (Fig. 3a and b).
This is indicative of the presence of DSBs, as shown by
use of the topoisomerase ll inhibitor VP-16 as a positive
control. In contrast, we repeatedly detected notable
losses of CHK1 protein levels in MTH1-knockdown
H23 and A549 cells relative to no siRNA and scramble
siRNA controls, which was significant in A549 relative
to no siRNA, but no indications of increased CHK1
phosphorylation in any cell line (Fig. 3c and d). The
basis of the CHK1 down-regulation is not clear. It may
indicate that MTH1-deficient H23 and A549 cells had
increased DNA replication stress levels, but that there
was a selective pressure to rapidly adapt and down-
a
b
c
d
Fig. 3 Alterations in DNA damage response signalling following MTH1 knockdown. Cells were grown in media without transfection reagent (no
siRNA), or transfected with MTH1 siRNA or scramble siRNA (Scr. siRNA). Western blots were performed 4 days post-transfection. Positive control
samples (+ve) were H23 cells treated with VP-16 (etoposide, 25 μg/ml), phleomycin (25 μg/ml) or hydroxyurea (2 mM) for 2 h. a and c Representative
Western blots. b pChk2(Thr68) band intensities from H522 samples were normalised to α-Tubulin, and expression levels calculated relative to no siRNA
samples. d Chk1 Western blot band intensities were normalized to α-Tubulin, and expression levels calculated relative to no siRNA samples. Mean
values and SD were calculated from the normalised values of the 3 independent experiments. Error bars represent SD. Asterisks represent a significant
difference between MTH1 siRNA and no siRNA normalised values (****P < 0.0001)
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regulate associated ATR-CHK1 activity to overcome
growth arrest. Transfection with the scrambled siRNA
caused increased Chk1 levels in H23 and H522 cells.
The reason for this is unclear, but it is very likely due to
unavoidable transfection-dependent siRNA-independent
effects on these particular cell lines as the commercially
available scrambled siRNA used (Silencer Select Nega-
tive Control No. 1, ThermoFisher Scientific) has no sig-
nificant sequence similarity to human gene sequences
and is confirmed to have minimal effects on gene ex-
pression. Nonetheless, the fact that lower Chk1 levels
were detected in H23 and A549 MTH1 siRNA cultures
even relative to the basal no siRNA (no transfection)
cultures demonstrates the strength of the phenotype. Fi-
nally, in our experimental conditions we could not de-
tect total CHK1 in MRC-5 cells (ATCC CCL-171), as
indicated by a previous study [45]. This may be due to
very low relative expression levels and/or an issue with
the particular antibody used.
MTH1 promotes H23 cell proliferation, but is dispensable
for NSCLC cell survival
Given the observed function for MTH1 in genome main-
tenance, we hypothesised that MTH1 would be ‘condition-
ally essential’ in NSCLC cells. To first test this, we assessed
if MTH1 was required for NSCLC cell proliferation using
the WST-1 assay, which measures the metabolic activity in
cell cultures. Concordant with the indication in Fig. 3 that
H23 and H522 cell lines are slightly sensitive to the non-
specific effects of transfection, the scrambled siRNA trans-
fected cultures showed 20% and 30% decreases in cell pro-
liferation, respectively (Fig. 4a and c). Nevertheless, MTH1
knockdown induced a significant 54% and 34% decrease in
H23 cell proliferation relative to the no siRNA and scram-
bled siRNA controls, respectively (Fig. 4a), indicating that
MTH1 is partially required for H23 growth. However, simi-
lar decreases in cell proliferation were not seen in A549,
H522 or MRC-5 cells relative to controls (Fig. 4b - d). This
contradicts previous data that suggested MTH1-deficient
A549 cells have dramatic proliferation defects [25].
To determine if MTH1 deficiency in NSCLC induces cell
death in addition to or rather than cell growth inhibition,
we measured apoptosis levels using annexin V (Fig. 5a).
We did not observe increased apoptosis levels in any
MTH1 knockdown cell cultures relative to the scrambled
siRNA controls irrespective of the p53-status of the line
(Fig. 5b - e). Consistent with previous observations (Figs. 3
and 4), H23 and H522 scrambled siRNA cultures demon-
strated minor MTH1-independent transfection-dependent
effects. The results of the apoptosis assay were confirmed
using another MTH1 siRNA that induces a similar de-
crease in MTH1 levels (Additional file 5).
Though MTH1 inhibition alone did not cause apop-
tosis, we propositioned that it would still enhance the
targeting and effectiveness of current chemotherapy
agents that induce oxidative stress [46, 47] and DNA
replication stress. The basis of this idea was that MTH1
inhibition leads to higher levels of oxidatively damaged
a c
b d
Fig. 4 MTH1 targeting reduces H23 cell proliferative capacity. WST-1 assay on cells grown in media without transfection reagent (no siRNA), or
5 days after transfection with MTH1 siRNA or scramble siRNA. a H23. b A459. c H522. d MRC-5. (a), (b) and (d) Values from 4 independent experiments
were used to generate final mean values and SD. (c) Values from 3 independent experiments were used to generate final mean values and SD. Error
bars represent SD. Asterisks indicate a significant difference relative to corresponding no siRNA controls (****P< 0.0001, ***P< 0.001, **P< 0.01, *P< 0.05)
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c
f
g
d
e
Fig. 5 MTH1 deficiency does not induce apoptosis or augment the cytotoxic effects of chemotherapy agents. Apoptosis assay to determine
viability of cells cultured for 4 days in media without transfection reagent (no siRNA), or following transfection with MTH1 siRNA or scramble
siRNA. Positive control of 48 h VP-16 treatment (+ve) also included. Harvested cells were dual stained with annexin V-FITC/propidium iodide (PI)
and assessed by flow cytometry. Annexin V is an apoptosis marker. PI is a DNA stain that is excluded from viable and early apoptotic cells. Percentage
values from independent experiments were used to calculate final mean values and SD. Error bars represent SD. a Representative bivariate plots of
H23 cells. b H23. c A549. d H522. e MRC-5. b and c 3 independent experiments performed. d and e 4 independent experiments performed. Asterisks
indicate a significant difference relative to corresponding no siRNA control (or no siRNA + DMSO control in case of VP-16). f H23 cells. 2 days after
transfection, 0.01 μM gemcitabine (Gem) or 5 μM cisplatin (Cis) were added to the appropriate cultures for the remaining 48 h (0.5% DMSO). 3
independent experiments performed with siRNA transfections (5 repeats for non-transfected samples). g H522 cell line. 2 days after transfection, 40 μM
gemcitabine (Gem) or 10 μM cisplatin (Cis) were added to the appropriate cultures for the remaining 48 h (1.5% DMSO). 3 independent experiments
performed with siRNA transfections and Cis and Gem treatments (4 repeats for untreated and non-transfected samples). f and g Asterisks in Scramble
siRNA and MTH1 siRNA samples indicate a significant difference between No treatment, Gem or Cis and corresponding no siRNA + DMSO, no siRNA +
Gem and no siRNA + Cis percentage values, respectively (****P < 0.0001, **P < 0.01, *P < 0.05)
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DNA in NSCLC cells but not normal cells, which when
combined with therapy-induced effects selectively pushes
the DNA damage levels over the cytotoxic threshold in
NSCLC cells. In particular, the mechanisms of action of
gemcitabine and cisplatin suggests the combining them
with the effects of MTH1 inhibition could lead to additive
or synergistic effects that would improve patient out-
comes. Gemcitabine is a chemical antimetabolite and
analogue of deoxycytidine that induces DNA replication
stress [48–50], and cisplatin leads to DNA replication de-
fects via the formation of DNA crosslinks [51, 52] and can
increase intracellular ROS levels possibly through mito-
chondrial dysfunction and activation of NAD(P)H oxidase
and superoxide production [53–55].
We treated H23 and H522 MTH1 knockdown cells
with gemcitabine or cisplatin and monitored apoptosis
levels. The effect on H522 was of particular interest, as
relative to H23 and A549, this cell line displays much
higher resistance to etoposide, gemcitabine and hydro-
gen peroxide (Fig. 5 and Additional file 6). Despite our
predictions, a combination of MTH1 knockdown with
either gemcitabine or cisplatin treatment did not lead to
significant increases in cell death levels relative to the
treated scramble siRNA controls (Fig. 5f and g). These
results were reproducible with a different MTH1 siRNA
(Additional file 5). This demonstrates that the oxidative
DNA damage induced by MTH1 deficiency in NSCLC
cells does not sufficiently sensitise them to the effects of
current therapeutic agents.
TH287 and TH588 MTH1 inhibitors have variable effects
on NSCLC cell lines
Using siRNA to assess the effects of MTH1 deficiency
on lung cell lines had uncovered some observations that
agreed with our predictions, but also uncovered some
unexpected results. To confirm our findings, we simi-
larly used the small molecule MTH1 inhibitors, TH287
and TH588, which were previously shown to lead to a
dramatic increase in oxidatively damaged DNA and loss
of viability in cancer cells but not primary human fibro-
blasts [22, 38].
When NSCLC and MRC-5 cell lines were treated with
the same dose (10 μM) of TH287 and TH588, an ob-
servable though not significant increase in the levels of
oxidatively damaged DNA was evident only in H23 cells
(Fig. 6a - d), implying that TH287 and TH588 treat-
ments did not lead to increased oxidatively damaged
DNA in H522, A549 or MRC-5 cells. There was no in-
crease in SSB levels in any cell line following TH287 or
TH588 treatment (Fig. 6a - d), which contrasts with a
previous observation in U2OS osteosarcoma cells [22].
We next assessed if the levels of oxidatively damaged
DNA correlated apoptosis induction. Indeed, TH287 and
TH588 induced significant 3.2 and 3.0-fold increases in
apoptosis levels in H23 cells, respectively (Fig. 6e), and
did not affect A549 cells (Fig. 6f ). However, significant 2.
8 and 3.5-fold increases in apoptosis levels were also ob-
served in inhibitor-treated H522 cells (Fig. 6g), indicat-
ing that levels of DNA oxidation were not the major
basis of the cytotoxic effects. Normal MRC-5 lung fibro-
blasts did not exhibit any apoptotic response to TH287
and TH588 (Fig. 6h), agreeing with the original sugges-
tion that TH287 and TH588 are not cytotoxic to normal
cells [22]. Collectively, these data suggest that TH287
and TH588 at the dose used induce cell death in p53-
mutated cancer cells through ‘off-target effects’ rather
than inhibition of MTH1, and do not induce cell death
in p53-proficient NSCLC cells and normal cells.
Discussion
In this study we tested the potential of a new targeted
therapy strategy for NSCLC, whilst simultaneously ana-
lysing opposing opinions within the field regarding the
conditionally essential requirements for MTH1 in cancer
cells and whether the current pursuit of MTH1 inhibitor
development is likely to yield effective therapeutic agents
[1, 32, 35]. We show that MTH1 does indeed have a
NSCLC-specific role for maintaining genome stability.
The basis of this cancer-specificity remains unclear, as
DNA oxidation levels in MTH1-deficient lung cells do
not correlate with background ROS levels. This goes
against the current model [32], and suggests that per-
haps the NSCLC-specific effect could be due to down-
stream defects in removing the oxidatively damaged
DNA induced in the cancer cell lines [56, 57]. Despite
the functional role for MTH1 in NSCLC cells, we show
that MTH1 deficiency ultimately does not cause NSCLC
death, either alone or when combined with other thera-
peutic agents. One possibility for this could have been
that the cell culture media used contained sodium pyru-
vate, a ROS scavenger. However, we do not believe this to
be the case as sodium pyruvate scavenges extracellular
ROS rather than intracellular endogenous ROS [37, 58],
and from what we can tell, other MTH1 studies that re-
ported cytotoxic effects associated with MTH1 also used
media containing sodium pyruvate [11, 22, 29]. Ultimately,
our work argues that MTH1 inhibitors will likely not be ef-
fective therapeutic agents. Instead, given that we show that
MTH1 deficiency in NSCLC cells induces non-cytotoxic
DNA oxidation and DDR alterations, we propose that
treating NSCLC patients with MTH1 inhibitors could ac-
tually provide an environment for further mutation accu-
mulation to drive cancer heterogeneity and evolution. In
accordance with this proposition, MTH1-knockdown in
human B lymphoblastoid cells induces a higher mutation
rate but not cell death after UVA-induced oxidative stress
[59], while MTH1 overexpression repressed the DNA-
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replication-dependent mutator phenotype in mismatch-
repair-defective colorectal cancer cells [60].
The increases in oxidatively damaged DNA in NSCLC
cell lines following MTH1 knockdown was relatively
small (Fig. 2). However, the alterations in DDR signaling
indicate that this was enough to disrupt DNA replication
and lead to secondary types of DNA damage such as
DSBs (Fig. 3). One proposed model for how this occur is
that oxidised DNA bases induce DNA replication stress,
which is defined as defective DNA replication fork pro-
gression [61, 62], and that this somehow subsequently
leads to DSBs [22, 27]. It is possible that DSBs can arise
from replication fork run-off at BER-induced SSBs,
which would lead to the generation of one-ended broken
DNA replication forks in a mechanism analogous to
DSBs arising from Top1-DNA adducts [63]. Alterna-
tively, DNA replication forks may stall at sites of oxida-
tively damaged DNA and be cleaved by endonucleases
a e
b f
c g
d h
Fig. 6 Variable effects of TH287 and TH588 MTH1 inhibitors on DNA oxidation and apoptosis. a - d Fpg-modified alkaline comet assay. DMSO
(0.066% v/v) used as a vehicle control. Means ± SD calculated from 3 independent experiments. 200 randomly selected individual comets were
scored for each sample per experiment. Mean values calculated from 3 independent experiments were used to generate final mean values and
SD. Error bars represent SD. e - h Annexin V-FITC/PI apoptosis assay to determine cell viability. DMSO (0.5–1.5% v/v) or VP-16 (+ve) were applied
as vehicle controls and positive controls, respectively. 3 independent experiments performed (except 150 μM VP-16). Percentage values from each
experiment were used to calculate final mean values and SD. Error bars represent SD. Asterisks indicate a significant difference between treated
and untreated percentage values (****P < 0.0001, **P < 0.01, *P < 0.05).
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such as Mus81 to also generate one-ended broken repli-
cation forks [64, 65]. No matter how they arise, these
one-ended DNA DSBs on replicating chromosomes
would lead to Chk2 activation [65], and are potentially
highly genotoxic or cytotoxic as they may be very diffi-
cult to resolve. Concordantly, one-ended DNA DSBs are
linked to various types of mutations [66–69].
It is unclear why the DDR signaling alterations varied
between the MTH1-defective NSCLC lines (Fig. 3), but
given that different cancers already harbour many other
mutations and potentially DDR defects, the signaling
variances may simply reflect the differing abilities and
deficiencies in DDR functions in different cancers. Fur-
thermore, ultimately the ATM/CHK2 and ATR/CHK1
pathways are interlinked, as ATM-activating DSBs can
subsequently lead to ATR activation if they are resected
to generate ssDNA overhangs [70], and processing of
ATR-activating stalled forks can generate DSBs [64]. The
induction of phosphorylated CHK2 in H522 cells sug-
gests that DNA DSBs arise. Why this should only occur
or be detectable in H522 cells remains unclear. The rea-
sons for decreased total CHK1 levels in A549 and H23
cell cultures were surprising. Although DDR activation
following MTH1 knockdown was previously observed,
including phosphorylation of H2AX, 53BP1, ATM and
DNA-PKcs [11, 22, 24, 27], to our knowledge this is the
first time that a MTH1-knockdown-associated ‘switching
off ’ of the DDR has been observed. Induced deficiency
of a DDR factor may indicate that MTH1 knockdown in
A549 and H23 cells initially induces DNA replication
fork stalling and ATR/CHK1 activation, but that the
bulk of the cells efficiently turned off this cell cycle
checkpoint signaling by lowering CHK1 levels to con-
tinue proliferating. Given that CHK1 levels were de-
creased within 4 days of MTH1 knockdown, this would
not be enough for a mutation and clonal expansion to
occur within the population, suggesting CHK1 suppres-
sion occurs through another mechanism that may in-
volve changes in gene expression (epigenetic), RNA
processing, post-translational modifications and/or pro-
teosomal degradation. Accordingly, various stresses have
previously been linked to CHK1 degradation [71, 72].
There have been several contradictory and opposing
reports on the cytotoxicity of MTH1 deficiency using
various siRNA and shRNA sequences, cell lines and in-
hibitors [11, 22, 24, 26, 27, 29–31, 38], which were re-
cently summarized and compared in a review article
[32]. A critical finding of our work is, that despite
MTH1 deficiency causing genomic instability in NSCLC
cells and decreased H23 cell proliferation, there was a
lack of cytotoxicity associated with MTH1 knockdown
in all NSCLC cell lines (Fig. 5). A simple explanation for
this finding is that the levels of MTH1 knockdown in
our experiments were not sufficient enough to induce
MTH1 deficiency. Or, as already discussed, other factors
may be able to sufficiently compensate for MTH1 [43].
However, we do not believe either of these possibilities is
the basis of the disparities, as the 1.5- to 2-fold increase
in oxidatively damaged DNA damage (Fig. 2) is compar-
able to that in other studies that did detect loss of cancer
cell viability [11, 22, 26, 38]. Also, we performed our ex-
periments 4 days after transfection, which was before
MTH1-proficient cells could take over culture (as con-
firmed by Western blot, Fig. 1). Hence, we suggest that
the increased levels of genomic instability in MTH1-
deficient NSCLC cells is not sufficiently high enough to
induce cell death, rather it could promote further muta-
tions and heterogeneity. Overall, our data therefore
indicates that MTH1 inhibition will likely not be a suc-
cessful therapeutic strategy for many NSCLC patients
even when used in combination treatments. However, it
remains possible that the effects of MTH1 deficiency
vary considerably depending on circumstances. For ex-
ample, MTH1 inhibition may be more effective on can-
cer cells that exhibit very high oxidative stress or
particular possess mutations, and combining MTH1 in-
hibition with other specific agents or inhibitors (for ex-
ample, Chk2 inhibitors) may prove to be selectively
toxic.
The MTH1 small molecule inhibitors, TH287 or
TH588, were proposed to be effective for cancer cell kill-
ing due to MTH1 inhibition [22]. In our studies, TH287
and TH588 did induce apoptosis in 2 out of the 3
NSCLC cell lines tested, but this did not entirely correl-
ate with increases in oxidatively damaged DNA levels
(Fig. 6). This suggests that the effects on cell viability
may have been distinct from MTH1 inhibition. Accord-
ingly, the cytotoxicity of TH588 to melanoma cells was
recently suggested to correlate to endogenous ROS
levels but be independent of MTH1, as TH588 treat-
ment induced melanoma cell death but MTH1 knock-
down did not, and TH588-induced apoptosis is not
rescued by overexpressing MTH1 or introducing the
bacterial homolog of MTH1 that is not inhibited by
TH588 [73]. It was also recently proposed that TH287
or TH588 at the dose we used exert much of their cyto-
toxic effects through tubulin polymerisation defects [30],
though this conclusion was subsequently challenged as
TH588 does not induce cellular changes commonly as-
sociated with Paclitaxel-induced tubulin defects [38]. Re-
peating the TH287 and TH588 treatments at a lower
dose of 3 μM, which does not induce tubulin polymer-
isation defects [30], and over a longer time period may
more specifically assess the consequences of TH287/
TH588-induced MTH1 inhibition on NSCLC cells.
Nonetheless, other highly specific MTH1 inhibitors were
found to not be cytotoxic to cancer cells [29, 31]. This
not only supports the conclusion that MTH1 is not
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essential for NSCLC cell viability, but also strengthens
the argument that MTH1 inhibitors may not make ef-
fective therapeutic agents.
Conclusion
The importance of the MTH1 enzyme in cancer is a
highly controversial topic within current cancer research
and the focus of intense study. We show that MTH1 is
indeed selectively required in various NSCLC cell lines
to maintain genome integrity and support H23 cell pro-
liferation. However, unexpectedly, MTH1 is ultimately
not essential for NSCLC cell viability and does not alter
responses to current therapeutic agents. Thus, our work
indicates that MTH1 is likely not an effective therapeutic
target for NSCLC. On the contrary, inhibiting MTH1
may promote further mutation accumulation and disease
progression.
Additional files
Additional file 1: Endogenous MTH1 levels are similar in H23, H522,
A549 and MRC-5 cell lines. MTH1 band intensities in no siRNA samples
were normalized to corresponding α-Tubulin loading control bands (see
Fig. 1 for representative Western blot images). Mean values and SD were
calculated from the normalised values of independent experiments. Numbers
of independent experiments (n) are indicated. Error bars represent SD.
(PDF 221 kb)
Additional file 2: MTH2 levels are stable following MTH1 siRNA knockdown.
Western blots from a single confirmation experiment performed to determine
MTH2 protein levels in cell cultures grown in media without transfection
reagent (no siRNA), or following transfection with MTH1 siRNA or scramble
siRNA (n = 1). (PDF 1128 kb)
Additional file 3: Representative images of “Comets” and the
corresponding intensity profiles, showing (i) ~ 5% Tail DNA damage,
typical of the NSCLC cells treated with no siRNA or scramble siRNA, and
analysed by regular Fpg-modified alkaline comet assay (0.8 U Fpg/gel); and
(ii) comets showing ~ 10% tail DNA, typical of the NSCLC cells treated with
MTH1 siRNA. Superimposed on the Comet images are the image analysis
software (Komet 5.5, Andor Technology) determined boundaries demarcating
the ‘Comet head’ (pink circle) and ‘tail extent’ (vertical orange line) (Barber RC,
Hickenbotham P, Hatch T, Kelly D, Topchiy N, Almeida GM, et al. Radiation-
induced transgenerational alterations in genome stability and DNA damage.
Oncogene. 2006;25(56):7336–7342). % tail DNA = 100 - % head DNA; % head
DNA = (integrated optical head intensity / (integrated optical head intensity +
integrated optical tail intensity)) × 100. (PDF 1431 kb)
Additional file 4: MTH1 deficiency does not alter levels of oxidatively-
modified DNA following hydrogen peroxide treatment. Fpg-modified
alkaline comet assay to determine DNA damage levels in individual cells
grown in media without transfection reagent (no siRNA), or 4 days after
transfection with MTH1 siRNA or scramble siRNA. After 30 min hydrogen
peroxide treatment at 37 °C, samples were collected either immediately
or allowed to recover in fresh media. Means were calculated from 100
individual comets from a single experiment. Error bars represent SEM of
comet values. a H23. b H522. (PDF 328 kb)
Additional file 5: MTH1 knockdown with another siRNA similarly does
not induce apoptosis in H23 cells. a Western blots to determine MTH1
protein levels in H23 cell cultures grown in media without transfection
reagent (no siRNA), or following transfection with MTH1 siRNA (ThermoFisher
Scientific, S194633, oligonucleotide 5′- > 3′ sequences were sense UUAACUG
GAUGGAAGGGAAtt and antisense AUCCAGUUAAUUCCAGAUGaa) or
scramble siRNA. Representative day 4 blot shown. Day 4 MTH1 band
intensities were normalized to corresponding α-Tubulin loading control
bands, and then siRNA samples were normalised to corresponding no
siRNA bands. Numbers of independent experiments (n) are indicated.
Mean values were calculated from the normalised values of the independent
experiments. Error bars represent SD. Asterisks represent a significant
difference between MTH1 siRNA and corresponding no siRNA normalised
values (**P < 0.01, *P < 0.05). b Apoptosis assay to determine cell viability of
H23 cells cultured for 4 days in media without transfection reagent (no
siRNA), or following transfection with MTH1 siRNA (S194633) or scramble
siRNA. Harvested cells were dual stained with annexin V-FITC/PI and
assessed by flow cytometry to detect both early and late apoptosis. 2 days
after transfection, 0.01 μM gemcitabine (Gem) or 5 μM cisplatin (Cis) were
added to the appropriate cultures for the remaining 48 h. Positive control of
48 h VP-16 treatment (+ve) also included (n = 1). (PDF 436 kb)
Additional file 6: Apoptotic dose responses of H23 and H522 cell lines
to various genotoxic agents. Apoptosis assay to determine cell viability
following 48 h treatment with different agents. In addition, cells were
exposed to VP-16 for positive controls, and DMSO (0.5–2% v/v) and
untreated negative control samples were also included. Harvested cells
were dual stained with annexin V-FITC/PI and assessed by flow cytometry
to detect both early and late apoptosis. a Hydrogen peroxide treatment
of H23 and H522 cells. b Gemcitabine treatment of H23 and H522 cells.
c Cisplatin treatment of H23 and H522 cells. Percentage values from
independent experiments were used to calculate final mean values and
SD. Error bars represent SD. All experiments were repeated more than 3
times. Asterisks indicate a significant difference relative to corresponding
DMSO controls (****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05).
(PDF 423 kb)
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